In this interview we discuss preliminary results of the COMPASS trial, which used whole-genome sequencing and RNA sequencing to analyze the tumors of patients with advanced pancreatic ductal adenocarcinoma to identify possible first-line treatments.
Kyaw L. Aung, MBBS, PhD
Advertisement
Articles by Kyaw L. Aung, MBBS, PhD
Advertisement
Latest Updated Articles
COMPASS: Genomic Profiling Could Guide Treatment in Advanced Pancreatic CancerPublished: February 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears Phase 3 Lacutamab Protocol in Cutaneous T-Cell Lymphomas
2
Identifying and Pursuing Optimization of ADC Treatment in Cancer
3
Finding a “Sweet Spot” for Smoldering Multiple Myeloma Management
4
The Show and After Show: What's Happening at the 43rd Annual Chemotherapy Foundation Symposium?
5
